NCT05913323Completed
Measuring Lung Mechanics in Patients with COPD Using the REOM Handheld Portable Device
Measuring Lung Mechanics in Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the Rapid Expiratory Occlusion Method (REOM) Handheld Portable Oscillometer: a Cross-Sectional Study.
Source: ClinicalTrials.gov · Last updated 26 Sept 2024
Brief summary (registry, in English)
The purpose the study is to determine the agreement between the information obtained about lung mechanics (lung function) from the Rapid Expiratory Occlusion Monitor (REOM) handheld portable device with that obtained by conventional oscillometry as well as by pulmonary function testing (PFT), in patients with both 'mild' as well as 'very severe' forms of chronic obstructive pulmonary disease (COPD). This study also intends to study the user experience with this handheld portable device.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 17 (actual)
- First submitted
- 13 Jun 2023
- Start date
- Aug 2023
- Primary completion date
- Aug 2024
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Diseases
- COPD
- NCT number
- NCT05913323
What you commit to
- Study type: Observational
- Participants enrolled: 17
- From Aug 2023 to the primary completion date, Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of co-morbid asthma
- Chronic respiratory infection
Other
- No existing COPD diagnosis
- Current use of home oxygen
- Any acute exacerbation of COPD (AECOPD) experienced within 4 weeks of participation in the study
- Any contraindication to respiratory testing
- Inability to participate in reproducible measurements due to physical or cognitive barrier
Who the study is looking for
- Males and females aged ≥40 with COPD, former/current smokers with a ≥10 pack-year smoking history.
- Diagnosed with COPD by FEV1/FVC \< 0.7 using standard PFT post-bronchodilator testing, with either 'mild' ('GOLD 1': FEV1 ≥ 80% of predicted value) COPD or 'very severe' ('GOLD 4': FEV1 \< 30% of predicted value) COPD.
- Ability to provide informed consent.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Health Centre Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.